Ready, Aim, Fire! Cancer-Targeting Mechanism Underlies Promising UW-Madison Spinoff
University of Wisconsin–MadisonA spinoff called Cellectar Biosciences is developing molecules that bind to more than 60 types of cancer. Several are being tested in early-stage clinical trials, including one for brain cancer. These custom-made molecules can carry either a "flag" that shines brightly in standard medical scanners or a bit of radiation to kill the targeted cancer cells.